SCHEMBL6351074

SCHEMBL6351074

NC(Cc1ccccc1)C(O)C(F)(F)C(F)(F)C(F)(F)F

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC15A1 P46059 1/20 0.43
EPHX1 P07099 1/20 0.42
CSNK1E P49674 1/20 0.42
ALPI P09923 1/20 0.41
PKM P14618 1/20 0.41
PTGS1 P23219 1/20 0.41
XIAP P98170 1/20 0.41
SLC7A5 Q01650 1/20 0.41
SLC6A2 P23975 2/20 0.40
TAAR1 Q96RJ0 2/20 0.40
MAOA P21397 1/20 0.40
SLC6A4 P31645 1/20 0.40
SLC6A3 Q01959 1/20 0.40
SIGMAR1 Q99720 1/20 0.40
CYP2A6 P11509 1/20 0.40
ADORA2A P29274 1/20 0.40
ADORA1 P30542 1/20 0.40
KDM4E B2RXH2 1/20 0.40
LMNA P02545 1/20 0.40
MAPK1 P28482 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6556276 0.82 EPHX1 (0.48) SLC15A1EPHX1CSNK1EALPIPKM
SCHEMBL10622532 0.82 EPHX1 (0.48) SLC15A1EPHX1CSNK1EALPIPKM
SCHEMBL27345872 0.81 SLC15A1 (0.44) SLC15A1EPHX1CSNK1EALPIPKM
Hydrochloric Acid SCHEMBL5711578 0.81 EPHX1 (0.47) SLC15A1EPHX1CSNK1EALPIPKM
SCHEMBL7337442 0.78 KDM4E (0.49) SLC15A1EPHX1CSNK1EALPIPKM
SCHEMBL7275924 0.78 KDM4E (0.49) SLC15A1EPHX1CSNK1EALPIPKM
SCHEMBL7412831 0.77 SLC15A1 (0.50) SLC15A1EPHX1CSNK1EALPIPKM
SCHEMBL7412834 0.77 SLC15A1 (0.50) SLC15A1EPHX1CSNK1EALPIPKM
SCHEMBL5704604 0.76 EPHX1 (0.45) SLC15A1EPHX1CSNK1EALPIPKM
SCHEMBL5704599 0.76 EPHX1 (0.45) SLC15A1EPHX1CSNK1EALPIPKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6960575-B2 For use as inhibitors of chymase SANTEN PHARMACEUTICAL CO., LTD. (JP) 2005-11-01 US disclosed
US-20040097496-A1 Novel thiazine derivatives SANTEN PHARMACEUTICAL CO.,LTD. (JP) 2004-05-20 US disclosed
US-6713472-B1 2-OXO-1,2,3,4-TETRAHYDROPYRAZINE DERIVATIVES; CHYMASE INHIBITORS SANTEN PHARMACEUTICAL CO., LTD. (JP) 2004-03-30 US disclosed
EP-1211249-A1 NOVEL THIAZINE OR PYRAZINE DERIVATIVES SANTEN PHARMACEUTICAL CO., LTD. (JP) 2002-06-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040097496-A1 Novel thiazine derivatives CMA1, TPSD1, HRH4 SLC15A1 1713/4885EPHX1 1026/4885CSNK1E 148/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.